ProVent-14 Score for Patients on Mechanical Ventilation
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores the usefulness of the ProVent-14 score in predicting long-term outcomes for patients on a ventilator for at least 14 days. The ProVent-14 score uses specific health details to estimate the risk of death within a year. The study compares two groups: one uses the ProVent-14 score for predictions, while the other relies on usual methods. Ideal participants are ICU staff directly caring for patients on a ventilator for 14-16 days, excluding those with conditions like ALS.
As an unphased study, this trial provides a unique opportunity to contribute to research that could enhance patient care and outcomes.
Will I have to stop taking my current medications?
The trial information does not specify whether participants need to stop taking their current medications.
What prior data suggests that the ProVent-14 score is safe for use in predicting long-term outcomes for mechanically ventilated patients?
Research shows that the ProVent-14 score predicts the risk of death within a year for patients on a ventilator for 14 days. This score is not a drug or treatment, so it poses no safety concerns. Instead, it uses patient information to help doctors make predictions.
Past studies have tested the ProVent-14 score in various settings and found it effective. It helps doctors estimate a patient's chance of surviving after a year. As a decision-making tool, it does not cause side effects or require safety testing like a new drug.
Overall, the ProVent-14 score improves the accuracy of doctors' predictions about patient outcomes. There are no known risks or side effects because it is not a physical treatment but a method for assessing patient prognosis.12345Why are researchers excited about this trial?
Researchers are excited about the ProVent-14 score because it offers a new way to predict outcomes for patients on mechanical ventilation. Unlike the usual prognostic approach, which relies heavily on a clinician's experience and general guidelines, the ProVent-14 score provides a data-driven method to assess patient prognosis. This score integrates specific clinical factors to give a clear picture of a patient's likely trajectory, which could lead to more personalized care decisions. By offering a more objective and standardized assessment tool, it has the potential to improve decision-making and patient outcomes in critical care settings.
What evidence suggests that the ProVent-14 score is effective for predicting long-term outcomes in mechanically ventilated patients?
Research has shown that the ProVent-14 score reliably predicts the risk of death within one year for patients on a ventilator for at least 14 days. Studies indicate that this score can estimate death risk, with rates ranging from 7% to 75% based on the score level. It uses clinical data to help doctors make informed predictions about long-term outcomes. In this trial, participants will either use their usual prognostic approach or be guided by the ProVent-14 score to form a prognosis. Multiple studies have proven the ProVent-14 score accurate, suggesting it could be a valuable aid in making critical care decisions.13678
Are You a Good Fit for This Trial?
This trial is for ICU day-shift clinicians (attending physicians, fellow physicians, advanced practice providers, or nurses) who are caring for patients needing mechanical ventilation 14-16 days after intubation and not transitioning to comfort-focused care.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Prognostic Assessment
ICU clinicians assess patients using either their usual prognostic approach or the ProVent-14 score to predict one-year mortality
Follow-up
Participants are monitored for accuracy of mortality predictions and other secondary outcomes
What Are the Treatments Tested in This Trial?
Interventions
- ProVent-14 score
Find a Clinic Near You
Who Is Running the Clinical Trial?
Rush University Medical Center
Lead Sponsor
University of North Carolina, Chapel Hill
Collaborator